Fidelity Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Fidelity Investments's MLTX Position: Q3 2026 in Review
Fidelity Investments sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 143,559 shares — an estimated $2.35M sold.
Fidelity Investments first reported a position in MLTX in Q4 2021 and held it in 19 quarters. The position peaked at $343M in Q4 2024. 163 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Fidelity Investments reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
- Fidelity Investments sold 143,559 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $2.35M.
- Fidelity Investments first reported a position in MoonLake Immunotherapeutics in Q4 2021 and held it in 19 quarters.
- Fidelity Investments's MoonLake Immunotherapeutics position peaked at $343M in Q4 2024.
- 163 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.